Risk Factors Update Summary
- The Company may not use its net operating losses to offset future taxable income.
- The Company received FDA approval for its product for children weighing 10kg+ with AKI.
- The Company expects to generate interim study results by mid-fourth quarter 2024.
- The Company's accumulated deficit increased from $106 million to $131 million.
- The Company's negative working capital increased from $3 million to $8 million.
- The Company entered into a securities purchase agreement with 3i for convertible notes and warrants.
- The Company identified a material weakness in its internal control over financial reporting.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1831868&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.